These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 26051379)

  • 1. Meta-Analysis of Randomized Controlled Trials Comparing Risk of Major Adverse Cardiac Events and Bleeding in Patients With Prasugrel Versus Clopidogrel.
    Chen HB; Zhang XL; Liang HB; Liu XW; Zhang XY; Huang BY; Xiu J
    Am J Cardiol; 2015 Aug; 116(3):384-92. PubMed ID: 26051379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
    Roe MT; Goodman SG; Ohman EM; Stevens SR; Hochman JS; Gottlieb S; Martinez F; Dalby AJ; Boden WE; White HD; Prabhakaran D; Winters KJ; Aylward PE; Bassand JP; McGuire DK; Ardissino D; Fox KA; Armstrong PW
    Circulation; 2013 Aug; 128(8):823-33. PubMed ID: 23852610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials.
    Tang XF; Fan JY; Meng J; Jin C; Yuan JQ; Yang YJ
    Atherosclerosis; 2014 Apr; 233(2):568-578. PubMed ID: 24534451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selecting antiplatelet therapy at the time of percutaneous intervention for an acute coronary syndrome: weighing the benefits and risks of prasugrel versus clopidogrel.
    Salisbury AC; Wang K; Cohen DJ; Li Y; Jones PG; Spertus JA
    Circ Cardiovasc Qual Outcomes; 2013 Jan; 6(1):27-34. PubMed ID: 23212457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging antiplatelet therapies in percutaneous coronary intervention: a focus on prasugrel.
    Martin MT; Spinler SA; Nutescu EA
    Clin Ther; 2011 Apr; 33(4):425-42. PubMed ID: 21635989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study.
    Trenk D; Stone GW; Gawaz M; Kastrati A; Angiolillo DJ; Müller U; Richardt G; Jakubowski JA; Neumann FJ
    J Am Coll Cardiol; 2012 Jun; 59(24):2159-64. PubMed ID: 22520250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety analysis of new P2Y12 inhibitors versus clopidogrel in patients with percutaneous coronary intervention: a meta-analysis.
    Gan XD; Wei BZ; Fang D; Fang Q; Li KY; Ding SL; Peng S; Wan J
    Curr Med Res Opin; 2015 Dec; 31(12):2313-23. PubMed ID: 26402735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prasugrel, a third-generation P2Y12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary intervention.
    Isshiki T; Kimura T; Ogawa H; Yokoi H; Nanto S; Takayama M; Kitagawa K; Nishikawa M; Miyazaki S; Ikeda Y; Nakamura M; Saito S;
    Circ J; 2014; 78(12):2926-34. PubMed ID: 25342212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
    Prescrire Int; 2009 Oct; 18(103):193-5. PubMed ID: 19877380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prasugrel: a guide to its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention in the US.
    Lyseng-Williamson KA
    Am J Cardiovasc Drugs; 2012 Jun; 12(3):207-16. PubMed ID: 22583148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland.
    Klingenberg R; Heg D; Räber L; Carballo D; Nanchen D; Gencer B; Auer R; Jaguszewski M; Stähli BE; Jakob P; Templin C; Stefanini GG; Meier B; Vogt P; Roffi M; Maier W; Landmesser U; Rodondi N; Mach F; Windecker S; Jüni P; Lüscher TF; Matter CM
    Heart; 2015 Jun; 101(11):854-63. PubMed ID: 25794517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Network meta-analysis of prasugrel, ticagrelor, high- and standard-dose clopidogrel in patients scheduled for percutaneous coronary interventions.
    Steiner S; Moertl D; Chen L; Coyle D; Wells GA
    Thromb Haemost; 2012 Aug; 108(2):318-27. PubMed ID: 22627948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of obesity and the metabolic syndrome on response to clopidogrel or prasugrel and bleeding risk in patients treated after coronary stenting.
    Pankert M; Quilici J; Loundou AD; Verdier V; Lambert M; Deharo P; Bonnet G; Gaborit B; Morange PE; Valéro R; Dutour A; Bonnet JL; Alessi MC; Cuisset T
    Am J Cardiol; 2014 Jan; 113(1):54-9. PubMed ID: 24182762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New antiplatelet agents in the treatment of acute coronary syndromes.
    Sabouret P; Taiel-Sartral M
    Arch Cardiovasc Dis; 2014 Mar; 107(3):178-87. PubMed ID: 24630752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.
    Antman EM; Wiviott SD; Murphy SA; Voitk J; Hasin Y; Widimsky P; Chandna H; Macias W; McCabe CH; Braunwald E
    J Am Coll Cardiol; 2008 May; 51(21):2028-33. PubMed ID: 18498956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching acute coronary syndrome patients from prasugrel to clopidogrel.
    Kerneis M; Silvain J; Abtan J; Cayla G; O'Connor SA; Barthélémy O; Vignalou JB; Beygui F; Brugier D; Martin R; Collet JP; Montalescot G
    JACC Cardiovasc Interv; 2013 Feb; 6(2):158-65. PubMed ID: 23428007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ischaemia versus bleeding: the art of clinical decision-making.
    Stone GW
    Lancet; 2009 Feb; 373(9665):695-6. PubMed ID: 19249613
    [No Abstract]   [Full Text] [Related]  

  • 18. Gastrointestinal adverse events after dual antiplatelet therapy: clopidogrel is safer than ticagrelor, but prasugrel data are lacking or inconclusive.
    Serebruany VL; Dinicolantonio JJ; Can MM; Pershukov IV; Kuliczkowski W
    Cardiology; 2013; 126(1):35-40. PubMed ID: 23860246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials.
    Mariani M; Mariani G; De Servi S
    Expert Rev Cardiovasc Ther; 2009 Jan; 7(1):17-23. PubMed ID: 19105763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits from new ADP antagonists as compared with clopidogrel in patients with stable angina or acute coronary syndrome undergoing invasive management: a meta-analysis of randomized trials.
    Verdoia M; Schaffer A; Barbieri L; Cassetti E; Piccolo R; Galasso G; Marino P; Sinigaglia F; De Luca G
    J Cardiovasc Pharmacol; 2014 Apr; 63(4):339-50. PubMed ID: 24336016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.